Kura Oncology (NASDAQ:KURA) SVP Thomas James Doyle Sells 7,142 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 7,142 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the transaction, the senior vice president owned 145,167 shares in the company, valued at approximately $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Thomas James Doyle also recently made the following trade(s):

• On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total value of $50,746.02.

Kura Oncology Trading Down 1.2%

NASDAQ KURA opened at $8.47 on Wednesday. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $12.49. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The firm has a market cap of $737.06 million, a P/E ratio of -3.42 and a beta of 0.25. The stock’s 50-day moving average is $10.33 and its 200-day moving average is $9.05.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. Zacks Research cut Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Leerink Partners set a $20.00 target price on Kura Oncology and gave the company an “outperform” rating in a research report on Tuesday, January 13th. JMP Securities restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Finally, UBS Group raised their price target on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its stake in shares of Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Kura Oncology in the third quarter valued at $89,000. Jain Global LLC acquired a new stake in Kura Oncology in the third quarter valued at $91,000. Finally, Lazard Asset Management LLC grew its position in shares of Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock valued at $92,000 after acquiring an additional 7,189 shares during the period.

Kura Oncology News Summary

Here are the key news stories impacting Kura Oncology this week:

• Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.
• Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.
• Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.
• Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.
• Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.